Cefixime is a third generation oral cephalosporin antibiotic used to treat bacterial infections. It works by inhibiting the synthesis of bacterial cell wall peptidoglycan which is essential for maintaining cell integrity. By blocking the transpeptidase enzymes involved in cross linking of peptidoglycan strands the drug weakens the bacterial envelope and leads to cell lysis. This action primarily affects gram positive and gram negative organisms that are susceptible to its spectrum causing the elimination of the infection. The medication reduces inflammation associated with infection by clearing the causative bacteria from respiratory and urinary tracts. Overall its active ingredient disrupts cell wall formation which ultimately results in the death of susceptible bacteria and resolution of the underlying disease.

Cefixime is a third-generation oral cephalosporin antibiotic used in clinical practice. It belongs to the class of beta-lactam drugs that inhibit bacterial cell wall synthesis. The drug binds to penicillin-binding proteins which are essential enzymes for cross-linking peptidoglycan strands in the bacterial cell wall. By disrupting this structural component the medication causes the wall to weaken and leads to osmotic lysis of susceptible bacteria. This mechanism provides broad coverage against many gram-positive and gram-negative pathogens that cause respiratory and urinary tract infections. The antimicrobial activity results from the drug's ability to interfere with cell wall formation rather than any direct metabolic effect.

Many people experience mild fatigue after taking the medication. Headaches are also frequently reported. Some individuals notice mild nausea or stomach upset. Occasionally, dizziness or temporary changes in taste may occur. These reactions are generally short-lived and not severe. Most side effects resolve without medical intervention.

The most common side effects of medication often include mild nausea fatigue and headache. These reactions are typically short lived and may resolve on their own as the body adjusts. In clinical practice they are observed more frequently than serious adverse events. The prevalence can vary depending on the specific drug and individual patient factors. Most people experience only a few symptoms and do not require medical intervention. Understanding the likelihood of these effects helps patients make informed decisions about treatment.